

Please type a plus sign (+) inside this box → ☐

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**TRANSMITTAL
FORM**

(to be used for all correspondence after initial filing)

Application Number 09/856,009

Filing Date May 16, 2001

First Named Inventor Kozak et al.

Group-Art-Unit 2594

Examiner Name Sonya N. Wright

Total Number of Pages in This Submission

5

Attorney Docket Number

800.1012

RECEIVED

FEB 19 2003

TECH CENTER 1600/2900

ENCLOSURES (check all that apply)☐ Fee Transmittal Form☐ Fee Attached☒ Amendment / Response☐ After Final☐ Affidavits/declaration(s)☐ Extension of Time Request☐ Express Abandonment Request☐ Information Disclosure Statement☐ Certified Copy of Priority Document(s)☐ Response to Missing Parts/ Incomplete Application☐ Response to Missing Parts under 37 CFR 1.52 or 1.53☐ Assignment Papers (for an Application)☐ Drawing(s)☐ Licensing-related Papers☐ Petition☐ Petition to Convert to a Provisional Application☐ Power of Attorney, Revocation Change of Correspondence Address☐ Terminal Disclaimer☐ Request for Refund☐ CD, Number of CD(s) _____☐ After Allowance Communication to Group☐ Appeal Communication to Board of Appeals and Interferences☐ Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)☐ Proprietary Information☐ Status Letter☒ Other Enclosure(s) (please identify below):

- return receipt postcard

Remarks

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Name Davidson, Davidson & Kappel, LLC

Address 485 Seventh Avenue, 14th Floor

City New York

State NY

Zip Code 10018

Country USA

Telephone

(212) 736-1940

Fax

(212) 736-2427

Individual name Morey B. Wildes

Signature

Date February 6, 2003

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231 on this date: February 6, 2003

Typed or printed name Morey B. Wildes

Signature

Date

February 6, 2003

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

RECEIVED


FEB 19 2003

TECH CENTER 1600/2900

800.1012

Handwritten initials and signature: 478, JG, and a signature.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE



| | |
|-------------------|---|
| Applicants: | KOZAK, et al. |
| Serial No.: | 09/856,009 |
| Filed: | May 16, 2001 |
| For: | PHOSPHOLIPID DERIVATIVES OF NON-STEROIDAL ANTI- INFLAMMATORY DRUGS |
| Examiner: | Sonya N. Wright (Group Art Unit: 1626) |
| Confirmation No.: | 2594 |

Box Non-Fee Amendment
Commissioner for Patents
Washington, D.C. 20231

February 6, 2003

RESPONSE TO OFFICE ACTION

S I R:

In response to the Office Action dated January 6, 2003 regarding the above-identified patent application, Applicants hereby respond as follows:

REMARKS

Claims 1-33 are in this application.

In the Office Action dated January 6, 2003, the Examiner indicated that claims 1-33 were subject to a Restriction Requirement for lack of unity of invention under PCT Rule 13.1 and 13.2, and required that Applicants "elect a single invention to which the claims must be restricted." According to the Examiner, a precise listing of inventive groups of claims cannot be made due to the numerous variables in the claims and their divergent meanings. However, the